Dengue is a mosquito-borne viral disease of expanding geographical range and incidence.
The existence of four viral serotypes and the association of prior dengue virus infection with …

Dengue virus (DENV) is a mosquito-transmitted RNA virus responsible for 390 million
infections each year and significant morbidity and mortality throughout tropical and …

A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue
viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue …

Dengue is one of the most important emerging vector-borne viral diseases. There are four
serotypes of dengue viruses (DENV), each of which is capable of causing self-limited …

Dengue viruses (DENV) cause significantly more human disease than any other arbovirus,
with hundreds of thousands of cases leading to severe disease in thousands annually …

The genus flavivirus of the Flaviridae family includes several human pathogens, like
dengue, Zika, Japanese encephalitis, and yellow fever virus. These viruses continue to be a …

We have developed Convacell®—a COVID-19 vaccine based on the recombinant
nucleocapsid (N) protein of SARS-CoV-2. This paper details Convacell's® combined phase …

Our group developed a subunit vaccine candidate against dengue virus based on two
different viral regions: the domain III of the envelope protein and the capsid protein. The …

Secondary heterologous dengue infection is a risk factor for severe disease manifestations
because of the immune-enhancement phenomenon. Succeeding clinical infections are …

Virus-like particles (VLPs) are shell-like viruses that lack virus-specific genetic materials.
Many viral-structured proteins can assemble into VLPs, which mimic the overall structure of …